GEXNUSYN Trademark

Trademark Overview


On Wednesday, February 9, 2022, a trademark application was filed for GEXNUSYN with the United States Patent and Trademark Office. The USPTO has given the GEXNUSYN trademark a serial number of 97260153. The federal status of this trademark filing is ABANDONED - EXPRESS AFTER PUB as of Saturday, August 24, 2024. This trademark is owned by Pfizer Inc.. The GEXNUSYN trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use; pharmaceutical preparations for the treatment of muscular dystrophy
gexnusyn

General Information


Serial Number97260153
Word MarkGEXNUSYN
Filing DateWednesday, February 9, 2022
Status605 - ABANDONED - EXPRESS AFTER PUB
Status DateSaturday, August 24, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 29, 2022

Trademark Statements


Goods and ServicesPharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use; pharmaceutical preparations for the treatment of muscular dystrophy

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code8 - Abandoned
Class Status DateSaturday, August 24, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 100012192

Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events


Event DateEvent Description
Saturday, February 12, 2022NEW APPLICATION ENTERED
Tuesday, February 15, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, October 20, 2022ASSIGNED TO EXAMINER
Friday, October 21, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 9, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 29, 2022PUBLISHED FOR OPPOSITION
Tuesday, November 29, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 24, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, April 6, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, April 6, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, April 6, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, April 6, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, April 6, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, January 16, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, January 16, 2024SOU EXTENSION 2 FILED
Tuesday, January 16, 2024SOU EXTENSION 2 GRANTED
Thursday, January 18, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 3, 2023SOU TEAS EXTENSION RECEIVED
Monday, July 3, 2023SOU EXTENSION 1 FILED
Monday, July 3, 2023SOU EXTENSION 1 GRANTED
Wednesday, July 5, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 3, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, July 3, 2024SOU EXTENSION 3 FILED
Wednesday, July 3, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 3, 2024SOU EXTENSION 3 GRANTED
Friday, August 23, 2024TEAS EXPRESS ABANDONMENT RECEIVED
Saturday, August 24, 2024ABANDONMENT - AFTER PUBLICATION
Saturday, August 24, 2024ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION